Cited by 114HER2/EGFR in Cancer ResearchCancer Treatment and PharmacologyBreast Cancer Treatment Studies

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Lapatinib for Advanced or Metastatic Breast Cancer

Open access

Opdam, Frans L., Guchelaar, Henk-Jan, Beijnen, Jos H., Schellens, Jan H.M.·2012·The Oncologist

DOI 10.1634/theoncologist.2011-0461PMC PMC3336826

Open this paper in CoChat — free account

Abstract

Lapatinib is a potent reversible and selective inhibitor of the tyrosine kinase domains of epidermal growth factor receptor and human epidermal growth factor receptor (HER)-2 that exerts its action by competitive binding to the intracellular ATP-binding site of the receptor. It is registered for the treatment of advanced or metastatic HER-2+ breast cancer in combination with capecitabine and for hormone receptor–positive breast cancer in combination with an aromatase inhibitor. Lapatinib administered orally once daily is moderately to well tolerated, with rash and gastrointestinal adverse events as the main toxicities. In studies on the efficacy of lapatinib, direct comparisons between lapatinib and trastuzumab are lacking. Results of ongoing randomized phase III studies with lapatinib or trastuzumab in combination with taxanes as first-line agents for metastatic breast cancer as well as in the neoadjuvant and adjuvant settings are awaited.

Integrity signals

Registry

Crossref · 10.1634/theoncologist.2011-0461

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J. K., Lindquist, D. L., Chan, S. Y. T., Romieu, C. G., Pieńkowski, T., Jagiełło-Gruszfeld, A., Crown, J. P., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,458
A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)
Wood, E. R., Truesdale, A. T., McDonald, O. B., Yuan, D. Y., Hassell, A. M., Dickerson, S. H., Ellis, B., Pennisi, C., Horne, E., Lackey, K. E., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1168 · Cited by 1,125
Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer
Johnston, S. R. D., Pippen, J., Pivot, X. B., Lichinitser, M., Sadeghi, S., Dieras, V. C., Gómez, H., Romieu, G., Manikhas, A., Kennedy, M. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3734 · Cited by 1,023
Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
Blackwell, K., Burstein, H. J., Storniolo, A. M., Rugo, H. S., Sledge, G. W., Koehler, M. T., Ellis, C. E., Casey, M., Vukelja, S. J., Bischoff, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4437 · Cited by 940
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
Cameron, D., Casey, M., Press, M. F., Lindquist, D. L., Pieńkowski, T., Romieu, C. G., Chan, S. Y. T., Jagiełło-Gruszfeld, A., Kaufman, B., Crown, J. P., et al. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9885-0 · Cited by 795
Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study
von Minckwitz, G., du Bois, A., Schmidt, M., Maass, N., Čufer, T., de Jongh, F. E., Maartense, E., Zielinski, C. C., Kaufmann, M., Bauer, W., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6618 · Cited by 674
Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways
Xia, W., Mullin, R. J., Keith, B. R., Liu, L.-H., Ma, H., Rusnak, D. W., Owens, G., Alligood, K. J., & Spector, N. L. (2002) · Oncogene · doi:10.1038/sj.onc.1205794 · Cited by 671
Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas
Burris, H. A., Hurwitz, H. I., Dees, E. C., Dowlati, A., Blackwell, K., O’Neil, B. H., Marcom, P. K., Ellis, M. J., Overmoyer, B. A., Jones, S. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.16.584 · Cited by 619
Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer
Leo, A. D., Gómez, H., Aziz, Z., Zvirbule, Z., Bines, J., Arbushites, M. C., Guerrera, S., Koehler, M. T., Oliva, C., Stein, S. H., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.2578 · Cited by 417

Show all 33 references

Research works printed but not linked: 13

European Medicines Agency, Tyverb® Summary of Product Characteristics
U.S. Food and Drug Administration, Tykerb® Approval Letter 13–3-2007
U.S. Food and Drug Administration, Tykerb® Approval Letter 29–01-2010
U.S. Food and Drug Administration, Tykerb®. Clinical Pharmacology and Biopharmaceutics NDA review
U.S. Food and Drug Administration Center for Drug Evaluation and Research, Medical Review Tykerb®. 6–3-2007
European Medicines Agency, Assessment Report for Tyverb®. Procedure No. EMEA H/C/795, 2008
National Institute for Health and Clinical Excellence (NICE), Final Appraisal Determination: Lapatinib for the Treatment of Women With Previously Treated Advanced or Metastatic Breast Cancer
National Institute for Health and Clinical Excellence (NICE), Liverpool Review and Implementation Group. Lapatinib and Trastuzumab in Combination With an Aromatase Inhibitor for the First-Line Treatment of Metastatic Hormone Receptor Positive Breast Cancer Which Overexpresses HER-2
CFH-Rapport 11/34: Lapatinib (Tyverb®) in Combinatie met een Aromataseremmer
ClinicalTrials.gov ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2–06/N063D
Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer
Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study
Wikipedia, Bestand:Lapatinib.svg

Sorted by citations

Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism
Abourehab, M. A. S., Alqahtani, A. M., Youssif, B. G. M., & Gouda, A. M. (2021) · Molecules · doi:10.3390/molecules26216677 · Cited by 211
Potentials and future perspectives of multi-target drugs in cancer treatment: the next generation anti-cancer agents
Doostmohammadi, A., Jooya, H., Ghorbanian, K., Gohari, S., & Dadashpour, M. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01607-9 · Cited by 212
The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells
Kurimchak, A. M., Herrera-Montávez, C., Montserrat-Sangrà, S., Araiza-Olivera, D., Hu, J., Neumann-Domer, R., Kuruvilla, M., Bellacosa, A., Testa, J. R., Jin, J., et al. (2022) · Science Signaling · doi:10.1126/scisignal.abn2707 · Cited by 136
Recent strategies to overcome breast cancer resistance
Khan, M. M., Yalamarty, S. S. K., Rajmalani, B. A., Filipczak, N., & Torchilin, V. P. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104351 · Cited by 100
Adherence to targeted oral anticancer medications.
Geynisman, D. M., & Wickersham, K. E. (2013) · PubMed · Cited by 92
Antisense Oligonucleotides Targeting Angiogenic Factors as Potential Cancer Therapeutics
Le, B. T., Raguraman, P., Kosbar, T. R., Fletcher, S., Wilton, S. D., & Veedu, R. N. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.11.007 · Cited by 94
Combinatorial therapy discovery using mixed integer linear programming
Pang, K., Wan, Y., Choi, W. T.-S., Donehower, L. A., Sun, J., Pant, D. K., & Liu, Z. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu046 · Cited by 86
Individualized dosing of tyrosine kinase inhibitors: are we there yet?
de Wit, D., Guchelaar, H., den Hartigh, J., Gelderblom, H. A. J., & van Erp, N. P. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.09.007 · Cited by 84
Self-citation
Histology-agnostic drug development — considering issues beyond the tissue
Pestana, R. C., Sen, S., Hobbs, B. P., & Hong, D. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0384-0 · Cited by 82
Current Status of Anti–Human Epidermal Growth Factor Receptor 2 Therapies: Predicting and Overcoming Herceptin Resistance
Chung, A. P., Cui, X., Audeh, W., & Giuliano, A. E. (2013) · Clinical Breast Cancer · doi:10.1016/j.clbc.2013.04.001 · Cited by 77
Epidermal Growth Factor Receptor Inhibitors in Glioblastoma: Current Status and Future Possibilities
Ezzati, S., Salib, S., Balasubramaniam, M., & Aboud, O. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042316 · Cited by 71
Recent Advances in the Use of Metformin: Can Treating Diabetes Prevent Breast Cancer?
Hatoum, D., & McGowan, E. M. (2015) · BioMed Research International · doi:10.1155/2015/548436 · Cited by 67
Synthesis and biological evaluation of crown ether fused quinazoline analogues as potent EGFR inhibitors
Hu, S., Xie, G., Zhang, D. X., Davis, C. B., Long, W. S., Hu, Y., Wang, F., Kang, X., Tan, F., Ding, L., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.06.067 · Cited by 60
Lapatinib Induced Suicidal Death of Human Erythrocytes
Zierle, J., Bissinger, R., Egler, J., & Lang, F. J. W. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000438583 · Cited by 56
Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value
Serritella, A. V., Strohbehn, G. W., Goldstein, D. A., Lichter, A. S., & Ratain, M. J. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1853 · Cited by 58
Direct targeting of HSP90 with daurisoline destabilizes β-catenin to suppress lung cancer tumorigenesis
Huang, X., Yan, X., Zhang, Q., Hong, P., Zhang, W., Liu, Y.-P., Xu, W. W., Li, B., & He, Q. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.05.024 · Cited by 55
Co-targeting estrogen receptor and HER2 pathways in breast cancer
Mehta, A., & Tripathy, D. (2013) · The Breast · doi:10.1016/j.breast.2013.09.006 · Cited by 55
Quinazoline Based HDAC Dual Inhibitors as Potential Anti-Cancer Agents
Dhuguru, J., & Ghoneim, O. (2022) · Molecules · doi:10.3390/molecules27072294 · Cited by 53
Drug Repurposing Targeting Pseudomonas aeruginosa MvfR Using Docking, Virtual Screening, Molecular Dynamics, and Free-Energy Calculations
Vieira, T. F., Magalhães, R. P., Simões, M. V., & Sousa, S. F. (2022) · Antibiotics · doi:10.3390/antibiotics11020185 · Cited by 50
Paclitaxel for breast cancer therapy: A review on effective drug combination modalities and nano drug delivery platforms
Zenjanab, M. K., Alimohammadvand, S., Doustmihan, A., Kianian, S., Oskouei, B. S., Mazloomi, M., Akbari, M., & Jahanban‐Esfahlan, R. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105567 · Cited by 51
HER2 in Solid Tumors: More than 10 Years Under the Microscope; where are we now?
Martin, V., Cappuzzo, F., Mazzucchelli, L., & Frattini, M. (2014) · Future Oncology · doi:10.2217/fon.14.19 · Cited by 48
A Comprehensive Overview on Chemotherapy-Induced Cardiotoxicity: Insights into the Underlying Inflammatory and Oxidative Mechanisms
Nagy, A., Börzsei, D., Hoffmann, A., Török, S., Veszelka, M., Almási, N., Varga, C., & Szabó, R. (2024) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-024-07574-0 · Cited by 45
EGFR trafficking: effect of dimerization, dynamics, and mutation
Schultz, D. F., Billadeau, D. D., & Jois, S. D. S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1258371 · Cited by 48
Potential role of immunotherapy and targeted therapy in the treatment of cancer: A contemporary nursing practice
Dailah, H. G., Hommdi, A. A., Koriri, M. D., Algathlan, E. M., & Mohan, S. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24559 · Cited by 42
The Story of EGFR: From Signaling Pathways to a Potent Anticancer Target
Ramani, S., Samant, S., & Manohar, S. M. (2022) · Future Medicinal Chemistry · doi:10.4155/fmc-2021-0343 · Cited by 33
circRNAs in drug resistance of breast cancer
Mısır, S., Yaman, S. Ö., Petrović, N., Sümer, C., Hepokur, C., & Aliyazıcıoğlu, Y. (2022) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2022.027547 · Cited by 31
Multimodal Non-Surgical Treatments of Aggressive Pituitary Tumors
Nakano-Tateno, T., Lau, K. J., Wang, J. Z., McMahon, C., Kawakami, Y., Tateno, T., & Araki, T. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.624686 · Cited by 30
Impact of the Cancer Cell Secretome in Driving Breast Cancer Progression
Zahari, S., Syafruddin, S. E., & Mohtar, M. A. (2023) · Cancers · doi:10.3390/cancers15092653 · Cited by 30
Therapeutic significance of molecular hybrids for breast cancer research and treatment
Shagufta, & Ahmad, I. (2022) · RSC Medicinal Chemistry · doi:10.1039/d2md00356b · Cited by 27
2′‐Hydroxyflavanone inhibits in vitro and in vivo growth of breast cancer cells by targeting RLIP76
Singhal, J., Chikara, S., Horne, D. A., Salgia, R., Awasthi, S., & Singhal, S. S. (2018) · Molecular Carcinogenesis · doi:10.1002/mc.22894 · Cited by 26
A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas
Karavasilis, V., Kotoula, V., Pentheroudakis, G. E., Televantou, D., Lambaki, S., Chrisafi, S., Bobos, M., & Fountzilas, G. (2013) · Journal of Neurology · doi:10.1007/s00415-012-6812-z · Cited by 26
Breast Cancer Stem Cells and Tumor Heterogeneity: Characteristics and Therapeutic Strategies
Romaniuk-Drapała, A., Totoń, E., Taube, M., Idzik, M., Rubiś, B., & Lisiak, N. (2024) · Cancers · doi:10.3390/cancers16132481 · Cited by 27
In-silico studies of glutathione peroxidase4 activators as candidate for multiple sclerosis management
Alameen, A. A., Abdalla, M., Alshibl, H. M., AlOthman, M., Alkhulaifi, M. M., Mirgany, T. O., & Elsayim, R. (2022) · Journal of Saudi Chemical Society · doi:10.1016/j.jscs.2022.101554 · Cited by 24
Emerging Intrinsic Therapeutic Targets for Metastatic Breast Cancer
Li, J., Goh, E. L. K., He, J., Li, Y., Fan, Z., Yu, Z., Yuan, P., & Liu, D. (2023) · Biology · doi:10.3390/biology12050697 · Cited by 27
STAT3 axis in cancer and cancer stem cells: From oncogenesis to targeted therapies
Godugu, D., Chilamakuri, R., & Agarwal, S. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189461 · Cited by 26
Emerging EGFR antagonists for breast cancer
Lluch, A. M., Eroles, P., & Fidalgo, J. A. P. (2014) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2014.903919 · Cited by 23
Personalized treatment approach for HER2-positive metastatic breast cancer
Pandey, P., Chaudhary, R., Tripathi, D., Lavudi, K., Dua, K., Weinfeld, M., Lavasanifar, A., & Rajinikanth, P. S. (2024) · Medical Oncology · doi:10.1007/s12032-024-02504-4 · Cited by 26
Cisplatin, Gemcitabine, and Lapatinib as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer
Narayan, V., Mamtani, R., O’Keefe, S. J., Guzzo, T. J., Malkowicz, S. B., & Vaughn, D. J. (2015) · Cancer Research and Treatment · doi:10.4143/crt.2015.405 · Cited by 23
Predicting Lapatinib Dose Regimen Using Machine Learning and Deep Learning Techniques Based on a Real-World Study
Yu, Z. Y., Ye, X., Liu, H., Li, H., Hao, X., Zhang, J., Kou, F., Wang, Z., Wei, H., Gao, F., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.893966 · Cited by 22
A Review of Treatment-Induced Pulmonary Toxicity in Breast Cancer
Mo, H., Jazieh, K., Brinzevich, D., & Abraham, J. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.05.014 · Cited by 21
EGFR inhibitors across generations: Progress, challenges, and future directions
Deshmukh, V. G., Sapkal, S. B., Gadekar, S. S., & Deshmukh, V. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.142326 · Cited by 20
A Lipophilic Salt Form to Enhance the Lipid Solubility and Certain Biopharmaceutical Properties of Lapatinib
Singh, N., Chakravarti, R., Das, A., Gupta, S., Ghosh, D., & Datta, P. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00283 · Cited by 16
Tyrosine Kinase Inhibitors Are Promising Therapeutic Tools for Cats with HER2-Positive Mammary Carcinoma
Gameiro, A., Almeida, F., Nascimento, C., Correia, J., & Ferreira, F. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030346 · Cited by 14
Emerging Biomarkers and Targeted Therapies in Feline Mammary Carcinoma
Gameiro, A., Urbano, A. C., & Ferreira, F. (2021) · Veterinary Sciences · doi:10.3390/vetsci8080164 · Cited by 19
Development of a stable and high loaded liposomal formulation of lapatinib with enhanced therapeutic effects for breast cancer in combination with Caelyx®: In vitro and in vivo evaluations.
Saremi, S. S., Nikpoor, A., Sadri, K., Mehrabian, A., Karimi, M., Mansouri, A., Jafari, M., & Badiee, A. (2021) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2021.112012 · Cited by 12
Effects of Lapatinib on HER2-Positive and HER2-Negative Canine Mammary Carcinoma Cells Cultured In Vitro
Leis‐Filho, A. F., Lainetti, P. D. F., Kobayashi, P. E., Fonseca‐Alves, C. E., & Amorim, R. L. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13060897 · Cited by 12
Complex formulation strategies to overcome the delivery hurdles of lapatinib in metastatic breast cancer
Singh, N., Reddy, K. P., Das, P., Kishor, B. K., & Datta, P. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104315 · Cited by 12
Halogen‐based quinazolin‐4(3H)‐one derivatives as MCF‐7 breast cancer inhibitors: Current developments and structure–activity relationship
Upadhyay, R., Tandel, P. K., & Patel, A. B. (2024) · Archiv der Pharmazie · doi:10.1002/ardp.202400740 · Cited by 12
Glyceollins Trigger Anti-Proliferative Effects in Hormone-Dependent Aromatase-Inhibitor-Resistant Breast Cancer Cells through the Induction of Apoptosis
Walker, R. R., Patel, J. R., Gupta, A., Davidson, A. M., Williams, C. C., Payton‐Stewart, F., Boué, S. M., Burow, M. E., Khupse, R. S., & Tilghman, S. L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052887 · Cited by 12
Palindromic carbazole derivatives: unveiling their antiproliferative effect via topoisomerase II catalytic inhibition and apoptosis induction
Olszewski, M., Maciejewska, N., Kallingal, A., Chylewska, A., Dąbrowska, A., Biedulska, M., Makowski, M., Padrón, J. M., & Bagiński, M. (2024) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2024.2302920 · Cited by 11
Outcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant trastuzumab: A prospective multicenter study
Xu, B., Hu, X., Zheng, H. Y., Wang, X., Zhang, Q., Cui, S., Liu, D., Liao, N., Luo, R., Sun, Q., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9331 · Cited by 11
Multifaceted role of erlotinib in various cancer: nanotechnology intervention, patent landscape, and advancements in clinical trials
Mangla, B., Mittal, P., Kumar, P., & Aggarwal, G. (2024) · Medical Oncology · doi:10.1007/s12032-024-02414-5 · Cited by 12
Virtual Screening to Identify Novel Inhibitors of Pan ERBB Family of Proteins from Natural Products with Known Anti-tumorigenic Properties
Ahammad, I., Sarker, M. R. I., Khan, A. M., Islam, S., & Hossain, M. (2019) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-019-09992-3 · Cited by 10
Targeted Therapies Against Growth Factor Signaling in Breast Cancer
Du, J., Yu, Y., Zhan, J., & Zhang, H. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-6020-5_6 · Cited by 8
Bringing Cancer Serological Diagnosis to a New Level: Focusing on HER2, Protein Ectodomain Shedding and Neoepitope Technology
Wang, J., Willumsen, N., Zheng, Q., Xue, Y. W., Karsdal, M. A., & Bay‐Jensen, A. (2012) · Future Oncology · doi:10.2217/fon.12.161 · Cited by 8
Dual inhibition of HERs and PD-1 counteract resistance in KRASG12C-mutant head and neck cancer
Novoplansky, O., Jagadeeshan, S., Prasad, M., Yegodayev, K. M., Marripati, D., Shareb, R. A., Greenshpan, Y., Mathukkada, S., Lulu, T. B., Bhattacharya, B., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03227-0 · Cited by 8
Metastatic human epidermal growth factor receptor 2-positive breast cancer: Management, challenges, and future directions
Soleja, M., & Rimawi, M. F. (2016) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2016.09.005 · Cited by 7
Gold-capsuled polymeric nanomedicine for synergistic breast cancer photo-chemotherapy
Kaur, N., Puppala, E. R., Srivastava, R., Naidu, V. G. M., & Shanavas, A. (2022) · Journal of Nanoparticle Research · doi:10.1007/s11051-022-05640-y · Cited by 7
Targeted Therapies in Cancer Treatment
Cavalcanti, I. D. L., & Soares, J. C. S. (2021) · Springer eBooks · doi:10.1007/978-3-030-68334-4_5 · Cited by 7
Biomarker-driven drug repurposing for NAFLD-associated hepatocellular carcinoma using machine learning integrated ensemble feature selection
Ghosh, S., Mandal, S. D., & Thakur, S. (2025) · Frontiers in Bioinformatics · doi:10.3389/fbinf.2025.1522401 · Cited by 6
Leveraging computational approaches in identifying novel HER-2 + breast cancer potential therapeutics: integrating virtual screening and molecular dynamics simulation
Bolaji, O. Q., Adelusi, T. I., Ojo, T. O., Boyenle, I. D., Oyedele, A.-Q. K., Ogunjobi, T. T., Oyaronbi, A. O., Ayoola, S. O., & Ogunlana, A. T. (2025) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-024-00748-5 · Cited by 6
Efficacy of afatinib in a HER2 amplification-positive endometrioid adenocarcinoma patient– a case report
Zhou, L. Q., Ren, Y., Wang, X., Miao, D.-L., Lizaso, A., Li, H., Han‐Zhang, H., Qian, J., & Yang, H. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s206732 · Cited by 6
Design and Synthesis of Potent Anticancer Agents Using Coumarin‐Quinazolinone Based Scaffolds: Exploration of ADME Properties and Molecular Docking Studies
Babagond, V., Katagi, K. S., Akki, M., Reddy, D. S., Shanavaz, H., Jaggal, A., & Soumyashree, D. K. (2024) · ChemistrySelect · doi:10.1002/slct.202400435 · Cited by 6
Bioequivalence study with lapatinib powder for oral suspension and the original tablet formulation in cancer patients
Koch, K. M., Ferron‐Brady, G., Lemmon, C., Cartee, L., Hollyfield, H., D'amelio, A. M., Piepszak, A. M., Swaby, R. F., Curran, D. W., & Arya, N. (2014) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.139 · Cited by 6
Identification of Lapatinib Derivatives and Analogs to Control Metastatic Breast Cancer-specific to South Asian Population-a Pharmacogenomic Approach
Vyshnavi, A. M. H., & Namboori, P. K. K. (2021) · WSEAS TRANSACTIONS ON BIOLOGY AND BIOMEDICINE · doi:10.37394/23208.2021.18.6 · Cited by 6
Role of the Tumor Microenvironment in Mediating Resistance to Anti-HER2 Antibodies
Gupta, M. K., Gouda, G., & Vadde, R. (2024) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2024053419 · Cited by 5
Effect of Triton X-100 on the Electrochemical Behavior of Hydrophobic Lapatinib Used in the Treatment of Breast Cancer: A First Electroanalytical Study
Aksöz, B. E., & Dogan‐Topal, B. (2021) · Journal of The Electrochemical Society · doi:10.1149/1945-7111/ac0ec3 · Cited by 5
Enhanced anticancer effect of thymidylate synthase dimer disrupters by promoting intracellular accumulation
Marverti, G., Moschella, M. G., Belardo, A., Lamesta, M., Mercanile, G., Tagliazucchi, L., Aiello, D., Venturelli, A., Illuminati, D., Guerrini, R., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1477318 · Cited by 5
Unusual long-lasting cutaneous complete response to lapatinib and capecitabine in a heavily pretreated HER2-positive plurimetastatic breast cancer patient
Pizzuti, L., Sergi, D., Barba, M., & Vici, P. (2013) · Tumori Journal · doi:10.1177/030089161309900332 · Cited by 5
A comprehensive exploration of adverse reactions to lapatinib: a disproportionate analysis based on the FAERS database
Zhou, Y., Gong, J., Deng, X., Shen, L., Ge, A., Fan, H., Ling, J., Wu, S., & Liu, L. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2471515 · Cited by 5
Neuroinflammation as a Central Mechanism in Alzheimer’s Disease: Therapeutic Insights from Schiff Base Derivatives
Abdullah, S., See-Too, W. S., Mohidin, T. B. M., & Mohan, G. (2026) · Molecules · doi:10.3390/molecules31030465 · Cited by 4
An organotin indomethacin derivative inhibits cancer cell proliferation and synergizes the antiproliferative effects of lapatinib in breast cancer cells.
Mendoza, M. S., Camacho-Camacho, C., Rojas‐Oviedo, I., Prado-Garcı́a, H., Barrera, D., Martínez-Reza, I., Larrea, F., & Garcı́a-Becerra, R. (2020) · PubMed Central · Cited by 4
Review on EGFR-ERK1/2 signaling cascade: implications on cell proliferation in health and disease
Fetoh, M. E. A., Abdel‐Fattah, M. M., Afify, H., Ramadan, L. A. A., & Mohamed, W. R. (2023) · Egyptian Pharmaceutical Journal · doi:10.4103/epj.epj_52_23 · Cited by 4
A pharmacokinetic study on lapatinib in type 2 diabetic rats
Karbownik, A., Szałek, E., Sobańska, K., Klupczyńska, A., Plewa, S., Grabowski, T., Wolc, A., Moch, M., Kokot, Z. J., & Grześkowiak, E. (2017) · Pharmacological Reports · doi:10.1016/j.pharep.2017.09.003 · Cited by 4
A phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignancies
Lynce, F. C., Wang, H., Petricoin, E. F., Pohlmann, P. R., Smaglo, B. G., Hwang, J. J., He, A. R., Subramaniam, D. S., Deeken, J. F., Marshall, J. L., et al. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03947-7 · Cited by 4
Breast cancer metastatic dormancy and emergence, a role for adjuvant statin therapy
Beckwitt, C. H. (2018) · D-Scholarship@Pitt (University of Pittsburgh) · Cited by 3
High Grade Meningiomas: Current Therapy Based on Tumor Biology
García-Robledo, J. E., Ordóñez‐Reyes, C., Ruíz-Patiño, A., Muñoz, Á., Arrieta, O. G., Jiménez, E., Hakim, F., Gómez, D., Ramón, J. F., & Cardona, A. F. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100432 · Cited by 3
Breast Cancer Therapies: A Review
Adebayo, K. S., Ajao, J. J., Oderemi, O. M., & Ughagwu, K. P. (2024) · Asian Pacific Journal of Cancer Biology · doi:10.31557/apjcb.2024.9.1.53-59 · Cited by 2
HER-2 SMASH
Alandağ, C., Öztürk, A., Yulak, F., İnan, Z. D. Ş., Özkaraca, M., Lacın, B. B., & Altun, A. (2024) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-024-04726-9 · Cited by 2
The Potency of 4-Methyl-3-Benzoyl Allylthiourea as Anti-Breast Cancer: Molecular Dynamic Simulation, Cytotoxic Activity and its Selectivity Index
Widiandani, T., Delis, S., Mohammad, R. F. P., Purwanto, B., Siswandono, S., & Ifadotunnikmah, F. (2025) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2025.00171 · Cited by 2
Mechanisms of Action and Resistance of Trastuzumab in Breast Cancer
Hsu, J. L., & Hung, M. (2018) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-67932-7_3 · Cited by 2
scPharm: Identifying Pharmacological Subpopulations of Single Cells for Precision Medicine in Cancers
Tian, P., Zheng, J., Qiao, K., Fan, Y., Xu, Y., Wu, T., Chen, S., Zhang, Y., Zhang, B., Ambrogio, C., et al. (2024) · Advanced Science · doi:10.1002/advs.202412419 · Cited by 2
Text-mining-based feature selection for anticancer drug response prediction
Wu, G. C., Zaker, A., Ebrahimi, A., Tripathi, S., & Mer, A. S. (2024) · Bioinformatics Advances · doi:10.1093/bioadv/vbae047 · Cited by 1
Invasive Breast Cancer Therapy 2017: How Well Are We Hitting the Target?
Tanios, G. E., Burow, M. E., Collins‐Burow, B. M., & Morrison, D. G. (2017) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-70142-4_1 · Cited by 1
Development and Validation of a Multi-Level Computational Protocol for Drug Repurposing in the Treatment of Bacterial Infections
Vieira, T. F., Magalhães, R. P., & Sousa, S. F. (2021) · International Electronic Conference on Synthetic Organic Chemistry (ECSOC) · doi:10.3390/ecsoc-25-11728 · Cited by 1
A review of Lapatinib, a tyrosine kinase inhibitor, in HER2+ metastatic breast cancer treatment development
Huang, A. (2023) · Theoretical and Natural Science · doi:10.54254/2753-8818/6/20230205 · Cited by 1
Lapatinib-induced PRIDE complex: a new kid on the block
Sil, A., Sikder, B., Biswas, S. K., & Chandra, A. (2023) · Postgraduate Medical Journal · doi:10.1093/postmj/qgad064 · Cited by 1
Exploration of crucial stromal risk genes associated with prognostic significance and chemotherapeutic opportunities in invasive ductal breast carcinoma
Tang, G., Wang, Z., Geng, W., Yu, Y., & Zhang, Y. (2024) · Journal of Genetic Engineering and Biotechnology · doi:10.1016/j.jgeb.2024.100448 · Cited by 1
Epigenetic drugs
Cacabelos, R., Naidoo, V., Tellado, I., Corzo, L., Cacabelos, N., Cacabelos, P., Martínez-Iglesias, O. A., & Segre, R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-18722-3.00029-3 · Cited by 1
Isolation, Characterization, and Structural Assessment of Novel Isomeric Dimer Impurities Discovered During the Manufacture of Lapatinib Ditosylate Using Preparative HPLC, HRMS, and NMR Techniques
Yerla, R. R., Babu, M. S., Saravanakumar, M., Chormale, S., Krishnamurthy, K. S., & Sunitha, K. (2025) · Separation Science Plus · doi:10.1002/sscp.70101 · Cited by 1
Synergistic inhibition of SCR1- and ERBB2-driven brain metastatic breast cancer cells
Ansari, S. R., Jandial, Z., Wu, X., Liu, X., Chen, M. Y., & Ansari, K. I. (2019) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2018.68 · Cited by 1
Molecular Characterization of Male Breast Cancer
Johansson, I. (2013) · Lund University Publications (Lund University) · Cited by 1
INIBIDORES DAS TIROSINACINASES NA TERAPÊUTICA FARMACOLÓGICA
Saraiva, S., Morgado, S., & Morgado, M. (2015) · DOAJ (DOAJ: Directory of Open Access Journals) · doi:10.25756/rpf.v5i3.44
Paradigme de la prise en charge du cancer bronchique et de celle des autres cancers : homologies, analogies, dissemblances
Pujol, J.-L., Vignot, S., di Mercurio, J.-P., & Quantin, X. (2013) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(13)70454-3
O CANCRO DA MAMA METASTIZADO É CURÁVEL? A PROPÓSITO DE UM CASO CLÍNICO
Alexandra, V., & Gomes, R. D. C. (2013)
Fatores prognósticos e preditivos da resposta clínica e patológica em mulheres com carcinoma de mama submetidas a quimioterapia neoadjuvante
Resende, U. (2018) · doi:10.47749/t/unicamp.2018.1009985
Impacto del cambio en la expresión de biomarcadores, utilizados para la clasificación del cáncer de mama en subtipos intrínsecos, asociado al tratamiento neoadyuvante en el pronóstico de mujeres colombianas diagnosticadas en el Instituto Nacional de Cancerología entre los años 2013-2015
Vargas, L. R. (2021) · doi:10.11144/javeriana.10554.52893
Use of peroral form of vinorelbine in metastatic breast cancer – choice in favor of quality of life
Владимировна, Л. Е., Khoroshilov, M. V., Drobot, N. T., & Артамонова, Е. В. (2022) · Medical alphabet · doi:10.33667/2078-5631-2022-13-7-13
Nghiên cứu độc tính đơn liều của hạt nano phóng xạ Fe3O4@Lapatinib - 153Sm trên động vật thí nghiệm
Dung, N. T. K., Minh, P. T., Tùng, P. Đ., Thắng, N. Q., Ngoc, H. T., & Sơn, M. H. (2023) · Journal of 108 - Clinical Medicine and Phamarcy · doi:10.52389/ydls.v18iyhhn.1938
Synergistic Inhibition of Burkitt’s Lymphoma with Combined Ibrutinib and Lapatinib Treatment
Chae-Eun, Y. A. N. G., Kim, S. B., Jeong, Y., & Lim, J.-Y. (2023) · Korean Journal of Clinical Laboratory Science · doi:10.15324/kjcls.2023.55.4.298

Authors: Opdam, F. L., Guchelaar, H.-J., Beijnen, J. H., & Schellens, J. H. M.
Affiliations: Leiden University (NL)
Utrecht University (NL)
Corresponding author: Schellens, Jan H.M.
ORCID: Opdam, Frans L.
Guchelaar, Henk-Jan
Beijnen, Jos H.
Schellens, Jan H.M.
Venue: The Oncologist
Publisher: Oxford University Press (OUP)
Published: 2012-04-01
Volume: 17
Issue: 4
Pages: 536-542
ISSN: 1083-7159 (ISSN-L)
1549-490X
DOI: 10.1634/theoncologist.2011-0461
PMC: PMC3336826
OpenAlex: W2169052701
Cited by: 113
References: 33
Citations by year: 2026: 8 · 2025: 10 · 2024: 23 · 2023: 9 · 2022: 12 · 2021: 12 · 2020: 4 · 2019: 6 · 2018: 5 · 2017: 3 · 2016: 2 · 2015: 4 · 2014: 5 · 2013: 8 · 2012: 2
FWCI: 0.66
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
Locations: The Oncologist (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
Leiden Repository (Leiden University) (submittedVersion)
Topics: Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords: lapatinib, HER2-positive breast cancer, metastatic breast cancer, tyrosine kinase inhibitors, EGFR, HER2, capecitabine, aromatase inhibitors, hormone receptor-positive breast cancer, trastuzumab, drug toxicity, rash, gastrointestinal adverse effects, taxanes
MeSH terms: Lapatinib, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Female, Humans, Neoplasm Metastasis, Quinazolines, Protein Kinase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Lapatinib for Advanced or Metastatic Breast Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks